Multiple Sclerosis (MS) Demyelinating Disorder; Its Overview, Indications, Etiology, Pathophysiology and Clinical Pharmacotherapy

Author : Dr. Syeda Sarah Abbas, Dr. Safila Naveed, Dr. Fatima Qamar, Zohra Barket Ali, Sehrish Kirn, Sania Zehra, Dr. Syed Hameez Jawed

Multiple sclerosis (MS) is also called as demyelinating disorder in which myelin sheath of neurons affected which ultimately affects the cognitive impairment and cause mobility disorders. Worldwide the Multiple sclerosis influences 2.5 million citizens plus 400,000 Americans. The main cause is still unknown but the researchers find that due to genetic, immunologic and environmental factors, myelin sheath could be damage. The treatment protocol depends upon the severity and the symptoms of the disease. Certain medications like Natalizumab, Dimethyl fumarate etc is used to treat relapses in MS. In case of severe illnesses, the patient response is being discontinued then the doctor and pharmacist ought to prefer palliative care for the wellbeing of the patient. The main objective of this review study is to give a glance about the multiple features of this disease state, its morbidity and co-morbidity, types and proper management by appropriate medications in order to avoid any drug interaction and toxicity.

Full Text Attachment

Creative Commons License World Journal of Pharmaceutical Science is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at Permissions beyond the scope of this license may be available at